A Phase 2/3 interventional study of QL0911 and QL0911 plus Placebo in Cancer Treatment-Induced Thrombocytopenia, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment
Among 108 studies in Thrombocytopenia with a site in China — 42 open to participants now, 45 under way, 10 of them phase 3. Thrombocytopenia · China.
Among the 108 studies in Thrombocytopenia with a site in China, this one is the 10th largest by planned enrollment of the 96 interventional ones that give a count, is one of 9 that started in 2024, is one of 12 in phase 2/3, reaches primary completion later than 31 of the 44 other live ones, and was the 75th registered.
482 studies on the registry are indexed under Thrombocytopenia; 100 are open to participants now.
Browse Thrombocytopenia studies →42 of the 108 studies in Thrombocytopenia with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Jiangsu HengRui Medicine Co., Ltd. · Sites in China, United States, Bulgaria and 8 more countries
Peking University People's Hospital · Sites in China
Zhejiang Cancer Hospital · Sites in China
Peking University People's Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 47 · Phase 3 32 · Phase 4 11
First in 2006; this study’s year is marked. 9 started in 2024.
This study's planned enrollment of 235 is above the median of 54 across 334 interventional studies indexed under Thrombocytopenia.
Median enrollment 82 across the 96 interventional studies, 114 across the 12 observational. Of the 41 that completed or were terminated, 9 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 108 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 198 studies on the registry; 120 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 3 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
6 of the studies in Thrombocytopenia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06456528Phase 3Qilu Pharmaceutical Co., Ltd.QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia | 2027-04-30 |
| NCT07442513Phase 3First Affiliated Hospital of Zhejiang UniversityComparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT | 2027-10-31 |
| NCT06898983Anhui Provincial HospitalEfficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia | 2027-01-31 |
| NCT07441720Zhejiang Cancer HospitalSafety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) | 2027-06-30 |
| NCT07586813Peking University People's HospitalRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors | 2027-10-31 |
Among the 108 studies in Thrombocytopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: QL0911
Drug: QL0911 plus Placebo
Drug: Placebo
QL0911
QL0911 plus Placebo
Placebo
The proportion of treatment responders.
Time frame: Randomization up to 80 days
Duration from the commencement of treatment to a platelet count ≥100×109/L
Time frame: Randomization up to 30 days
Proportion of subjects who could complete chemotherapy without dose modification and rescue therapy
Time frame: Randomization up to 150 days
Number of adverse events (AEs)/serious adverse events (SAEs)
Time frame: Randomization up to 150 days
Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QL0911
Qilu Pharmaceutical Co., Ltd. →